HemaSphere · 2025
3D Tumor microenvironment interaction reveals AP-1 complex regulation and contact-mediated reprogramming of bone marrow stromal cells in chronic lymphocytic leukemia.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Lindacher Jana, Hartebrodt Anne, Dingfelder Janin, Lukas Pascal, Würthner Laeschkir, Völkl Simon, Blumenthal David B, Graw Frederik, Amann Kerstin, Krumbholz Manuela, Haibach Martina, Wilke Jochen, Mackensen Andreas, Lutzny-Geier Gloria
Аннотация
Chronic lymphocytic leukemia (CLL) cells actively reprogram their tumor microenvironment (TME) to promote drug resistance and tumor progression. Tumor cell survival critically depends on heterotypic communication with benign cells in the microenvironment, particularly bone marrow-derived stromal cells (BMSCs). Our three-dimensional (3D) approach allows us to investigate spatially defined, mutual direct cell-cell interactions between CLL B cells, autologous T cells, and BMSCs, forming complex scaffold-like structures reminiscent of in vivo conditions. Here, we observe that CLL B cells localized in the core regions of 3D structures upregulate the AP-1 transcription factor complex, which confers significant protection against therapy-induced cell death. Additionally, regulatory T cells (Treg) and follicular T helper cells (TfH) are more abundant in the core regions. CLL B cells, in turn, induce contact-mediated reprogramming of BMSCs, resulting in a novel, distinct BMSC population with inflammation, bone immune evasion, and cancer-associated fibroblast-like features. Our findings reveal critical mechanisms by which CLL cells exploit the TME to drive pathogenesis and therapeutic resistance using realistic 3D setups, highlighting the potential of targeting AP-1 and the stromal compartment in future treatment strategies.